. 2022 Mar 29;15:2075–2086. doi: 10.2147/JIR.S349502

Table 5.

Mean IBD Activity Index and Mean Inflammatory Measures for Patients During Study Period

Elements	Enrollment			2 Week			4 Week			8 Week			12 Week
Elements	GI	GII	P	GI	GII	P	GI	GII	P	GI	GII	P	GI	GII	P
PCDAI	38.3±9.5	38.6±11.2	0.93	19.1±12.6	21.5±10.8	0.74	12.7±7.5	14.8±9.2	0.3	9.7±11.2	11.3±10.5	0.04*	6.4±8.1	10.8±7.4	0.02*
PCDAI	38.3±9.5	38.6±11.2	0.93	19.1±12.6	19.2±11.1	0.82	12.3±9.7	15.2±8.0	0.55	8.3±4.7	10.6±5.4	0.2	7.6±11.2	9.2±7.5	0.04*
PUCAI	37.9±15.4	39.1±14.9	0.96	18.7± 8.8	19.2±11.1	0.82	12.3±9.7	15.2±8.0	0.55	8.3±4.7	10.6±5.4	0.2	7.6±11.2	9.2±7.5	0.04*
CRP(N< 10 mg/L)	25.4±18.1	27.1±20.5	0.98	19.6±21.1	22.3±16.5	0.66	12.3±11.3	16.1±14.9	0.1	4.4±2.7	8.1±3.0	0.04*	3.1±0.9	5.8±3.5	0.01*
ESR(N 0–20 mm/h)	14.3±12.1	15.7±10.9	0.92	11.7±9.9	11.9±10.0	0.77	10.2±8.8	10.0±7.8	0.8	8.3±6.3	8.2±7.5	0.88	6.5±5.2	5.8±6.1	0.66
Albumin(N 3.5–5.5 g/dL)	4.2±0.9	4.1±0.88	0.91	4.2±0.88	4.2±0.91	0.83	4.3±0.78	4.2±0.77	0.69	4.4±0.45	4.3±0.7	0.77	4.3±0.68	4.4±0.37	0.82
Calprotectin(N< 50 µg/g)	622.4±411.5	645.8± 435.7	0.88				405.4±168.8	488.2±230.9	0.06				221.5±88.5	395.7±194.4	0.03*
TNF-α (pg/mL)	18.9±3.8	17.8±2.7	0.696				14.7±4.0	14.2±3.5	0.88				10.1±2.5	12.2±3.8	0.04*
IL-17 (pg/mL)	27.1±4.2	26.9±4.6	0.24				22.8±5.5	22.1±6.2	0.6				14.5±3.7	18.2±4.7	0.02*
IL-10 (pg/mL)	6.5±1.3	6.6±1.4	0.652				4.9±1.5	5.0±1.7	0.82				4.1±0.9	4.6±1.1	0.1
IL-12 (pg/mL)	122.3±18.7	118.1±13.4	0.961				98.2±21.1	99.3±18.8	0.56				77.2±14.5	84.4±16.2	0.02*
IL-23 (pg/mL)	60.7±9.6	58.9±7.7	0.591				51.4±12.2	54.4±10.2	0.66				38.8±11.5	44.6±12.1	0.03*

Note: P* significant ≤0.05.